Can a Two-Dose drug delay type 1 diabetes as well as a 14-Day treatment?
NCT ID NCT07216391
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two drugs, ATG and teplizumab, to see if they can delay or prevent type 1 diabetes in people who are at high risk. About 60 participants aged 4 to 35 will receive either two infusions of ATG or 14 daily infusions of teplizumab. Researchers will monitor them for at least a year to see how well each drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Antithymocyte Globulin (ATG) or Teplizumab
What this could lead to
If successful, this could offer another treatment option to delay the onset of type 1 diabetes in people at high risk.
What could go wrong
This is a small, early-phase study with only 60 participants. It may not show a clear benefit, and the effects may not last long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Florida
Gainesville, Florida, 32610, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact